drugset / Trial / NCT06349980
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Timeline
- Start
- 2024-08-05
- Primary completion
- 2027-02-10
- Completion
- 2027-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | HLX53 | Protein / enzyme biologic | 1000 mg | Intravenous |
| Subject | HLX53 | Protein / enzyme biologic | 2000 mg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |